Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
Authors
Keywords
Drug metabolism, Enzyme metabolism, Pediatrics, Adverse events, Variant genotypes, Adverse reactions, Blood plasma, HIV
Journal
PLoS One
Volume 12, Issue 9, Pages e0181316
Publisher
Public Library of Science (PLoS)
Online
2017-09-09
DOI
10.1371/journal.pone.0181316
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years
- (2016) Man Luo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation
- (2015) Francoise Pinillos et al. BMC INFECTIOUS DISEASES
- Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa
- (2015) Phumla Z. Sinxadi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study
- (2015) LANCET INFECTIOUS DISEASES
- Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz
- (2014) Panjasaram Naidoo et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
- (2014) Jackson K. Mukonzo et al. PLoS One
- Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy
- (2013) Zara Shubber et al. AIDS
- Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in HIV-Infected Children
- (2013) Ahmed Hamed Salem et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
- (2013) Jackson K Mukonzo et al. BMC INFECTIOUS DISEASES
- Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism
- (2013) C. Sukasem et al. INFECTION
- High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients
- (2013) Marelize Swart et al. Pharmacogenetics and Genomics
- Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
- (2013) Eliford Ngaimisi et al. PLoS One
- Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
- (2013) Iris Usach et al. Journal of the International AIDS Society
- Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
- (2012) Emily R. Holzinger et al. Pharmacogenetics and Genomics
- ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients
- (2012) Marelize Swart et al. Frontiers in Genetics
- Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children
- (2011) M. Viljoen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pediatric Underdosing of Efavirenz
- (2011) Quirine Fillekes et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: A cross-sectional cohort study
- (2011) Lars Skov Dalgaard et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
- (2010) Heather J. Ribaudo et al. JOURNAL OF INFECTIOUS DISEASES
- Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients
- (2010) Laure Elens et al. PHARMACOGENOMICS
- CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
- (2009) Awewura Kwara et al. AIDS
- Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children?
- (2009) D. Hirt et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
- (2009) Jackson K. Mukonzo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started